Blueprint’s pipeline also includes other promising candidates such as BLU-808, an oral wild-type KIT inhibitor being developed for chronic spontaneous urticaria (CSU) and other allergic conditions.

Blueprint Medicines (NASDAQ: BPMC) Corporation, a commercial-stage biotechnology company with a market capitalization of $8.27 billion, has been making significant strides in the pharmaceutical ...

In conclusion, Blueprint Medicines stands at a pivotal juncture with its recent acquisition by Sanofi and the continued success of Ayvakit. The stock has demonstrated strong momentum, with a 37.31% ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 potential. Click for more on SNY and BPMC.

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines ...

Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer ...

Sanofi is acquiring Blueprint Medicines Corp. and its rare immunology disease treatment, which is already approved in the U.S. and European Union.

Blueprint Medicines (BPMC) shares are soaring after Sanofi (SNY) agreed to acquire the company for up to $9.5 billion. Boeing (BA) shares were upgrade to Buy from Neutral at Bank of Bank of America.

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts ...